TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00314106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melanoma Reactive TIL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melanoma Reactive TIL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/ day x 2 days intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/ day x 2 days intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 720,000 IU/kg/dose every 8 hours for up to 15 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 720,000 IU/kg/dose every 8 hours for up to 15 doses
Study: NCT01191216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01663753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET
Study: NCT03693729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS
Description: Participants will complete a metamemory and memory task

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: Participants will complete a metamemory and memory task

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS
Description: Participants will complete a metamemory and memory task
Study: NCT00401362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone
Description: Dose 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone
Description: Dose 2
Study: NCT02614469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: Inosine, 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: Inosine, 1000 mg
Study: NCT02047318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001 (Maralixibat)
Description: Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
Study: NCT01682044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT00314106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous x 5 days
Study: NCT03313232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%
Description: A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%
Description: A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROAT with oxidized R-limonene at 1%
Description: A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
Study: NCT05662709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth extraction in the most atraumatic way
Study: NCT00314106

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1200 total body irradiation (TBI)
Description: 1200 cGY total body radiation
Study: NCT05662709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation with L-PRF
Description: Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
Study: NCT02043600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12-week Hatha Yoga intervention 90 minutes once a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care
Description: Self-care books are provided for self-directed use
Study: NCT02398279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: Experimental supplement
Study: NCT03533933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen matrix
Description: Mucograft collagen matrix combined with coronal advanced flap

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous connective tissue graft
Description: Soft tissue harvesting from patient palate with coronal advanced flap
Study: NCT01039441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of bupivacaine
Description: A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 removal by means of a pulmonary recruitment maneuver
Description: CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT02507284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04002895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax
Description: Single oral dose of 80 mg \[14C\]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from \[14C\]-foliglurax powder for oral solution)
Study: NCT02324595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic interval debulking surgery
Description: Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered
Study: NCT00877864

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High volume combined aerobic/resistance exercise
Description: High volume combined aerobic/resistance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low volume combined aerobic/resistance exercise
Description: Low volume combined aerobic/resistance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High volume combined A/R exercise, printouts, pedometers
Description: High volume combined aerobic/resistance exercise, printouts, pedometers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low volume combined A/R exercise, printouts, pedometers
Description: Low volume combined aerobic/resistance exercise, printouts, pedometers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed PA information, pedometers and step log group
Description: Printed PA information, pedometers and step log group

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No exercise program provided by the study
Study: NCT03206138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7
Description: Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E, Imiquimod
Description: 1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
Study: NCT00884442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)
Description: 60 mg nifedipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)
Description: 60 mg nifedipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)
Description: 60 mg nifedipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)
Description: 60 mg nifedipine
Study: NCT02398279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: Experimental supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules in the same color and shape with the experimental supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules in the same color and shape with the experimental supplement
Study: NCT04390932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced TA
Description: The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited TA
Description: The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise protocol.
Description: Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise protocol.
Description: Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
Study: NCT03521895

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Patients observed with regular and irregular treatment course
Study: NCT04125264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound
Description: Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
Study: NCT00128505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study: NCT00689442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 600 mg and atorvastatin 20 mg
Description: * JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and atorvastatin 20 mg
Description: * Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Study: NCT02299401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women will receive three 800 mcg doses of misoprostol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women will receive three 800 mcg doses of misoprostol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-quantitative pregnancy test
Description: All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
Study: NCT01682044

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study: NCT00963807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT
Description: Undergo FDG PET/CT, FLT PET/CT and thoracic CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: Undergo FDG PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT
Description: Undergo FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Undergo FDG PET/CT and FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo surgery
Study: NCT01999673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for bavituximab)
Study: NCT02919306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-Mosaic
Description: Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
Study: NCT01865734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy after initial podiatry visit
Description: Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care provided by podiatry
Description: Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
Study: NCT00025038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo total body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-unit umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo allogeneic cord blood transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02299401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-quantitative pregnancy test
Description: All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
Study: NCT01967368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intanza
Description: Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
Study: NCT01967368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip
Description: Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
Study: NCT03758885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nolasiban
Description: Nolasiban single oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single oral administration
Study: NCT03553966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic
Description: Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning teeth
Description: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restorative dentistry
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative dentistry
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study: NCT03780400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical Activity Care Pathway
Description: The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
Study: NCT01642810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioural therapy
Description: Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Will vary per participant
Description: Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Will vary per participant
Description: Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
Study: NCT03584945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.

Intervention type: OTHER
Group type: OTHER
Intervention: Community Referral as appropriate
Description: Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment